Acute myeloid leukemia: lack of predictive value of sequential quantitative MR imaging during treatment.

Radiology ◽  
1995 ◽  
Vol 197 (1) ◽  
pp. 301-305 ◽  
Author(s):  
B C Vande Berg ◽  
P J Schmitz ◽  
J M Scheiff ◽  
B J Filleul ◽  
J L Michaux ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Mr Imaging ◽  
Predictive Value ◽  
Myeloid Leukemia ◽  
Quantitative Mr Imaging ◽  
Quantitative Mr ◽  
Acute Myeloid

Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis

2016 ◽  
Vol 35 (4) ◽  
pp. 810-813 ◽  
Author(s):  
Uday Deotare ◽  
Marwan Shaheen ◽  
Joseph M. Brandwein ◽  
Bethany Pitcher ◽  
Suzanne Kamel-Reid ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Predictive Value ◽  
Myeloid Leukemia ◽  
Single Center ◽  
Core Binding Factor ◽  
Binding Factor ◽  
Acute Myeloid

scholarly journals Pretreatment platelet count predicts survival outcome of patients with de novo non-M3 acute myeloid leukemia

PeerJ ◽  
2017 ◽  
Vol 5 ◽  
pp. e4139 ◽  
Author(s):  
Qianying Zhang ◽  
Kanchun Dai ◽  
Laixi Bi ◽  
Songfu Jiang ◽  
Yixiang Han ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Platelet Count ◽  
Predictive Value ◽  
Myeloid Leukemia ◽  
De Novo ◽  
Univariate Analysis ◽  
Survival Outcome ◽  
Cox Regression Analysis ◽  
High Platelet Count ◽  
Acute Myeloid

Background Pretreatment platelet count has been reported as a potential tool to predict survival outcome in several solid tumors. However, the predictive value of pretreatment platelet count remains obscure in de novo acute myeloid leukemia (AML) excluding acute promyelocytic leukemia (M3). Methods We conducted a retrospective review of 209 patients with de novo non-M3 AML in our institute over a period of 8 years (2007–2015). Receiver operating characteristic (ROC) curve analysis was used to determine the optimal platelet (PLT) cutoff in patients. We analyzed the overall survival (OS) and disease free survival (DFS) using the log-rank test and Cox regression analysis. Results By defining the platelet count 50 × 109/L and 120 × 109/L as two cut-off points, we categorized the patients into three groups: low (<50 × 109/L), medium (50–120 × 109/L) and high (>120 × 109/L). On univariate analysis, patients with medium platelet count had longer OS and DFS than those with low or high platelet count. However, the multivariate analysis showed that only longer DFS was observed in patients with medium platelet count than those with low or high platelet count. Conclusion Our findings indicate that pretreatment platelet count has a predictive value for the prognosis of patients with non-M3 AML.

scholarly journals Predictive value of integrin α7 for acute myeloid leukemia risk and its correlation with prognosis in acute myeloid leukemia patients

2019 ◽  
Vol 34 (4) ◽  
Author(s):  
Mingyue Zeng ◽  
Siruiyun Ding ◽  
Hui Zhang ◽  
Qianqian Huang ◽  
yi Ren ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Predictive Value ◽  
Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals Functional MR imaging of tumor angiogenesis predicts outcome of patients with acute myeloid leukemia

Leukemia ◽  
2005 ◽  
Vol 20 (2) ◽  
pp. 357-362 ◽  
Author(s):  
T T-F Shih ◽  
H-F Tien ◽  
C-Y Liu ◽  
W-P Su ◽  
W-K Chan ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Mr Imaging ◽  
Tumor Angiogenesis ◽  
Myeloid Leukemia ◽  
Functional Mr Imaging ◽  
Acute Myeloid

scholarly journals 2683. Evaluation of the Negative Predictive Value (NPV) of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Swab Screening in Acute Myeloid Leukemia Patients

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S942-S943
Author(s):  
Bailee Binks ◽  
Dayna McManus ◽  
Sarah Perreault ◽  
Jeffrey E Topal
Keyword(s):  
Staphylococcus Aureus ◽  
Acute Myeloid Leukemia ◽  
Antibiotic Therapy ◽  
Predictive Value ◽  
Myeloid Leukemia ◽  
Nasal Swab ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Nasal Swabs ◽  
Mrsa Infection ◽  
Acute Myeloid

Abstract Background Methicillin-Resistant Staphylococcus aureus (MRSA) nasal swabs are utilized to guide discontinuation of empiric MRSA therapy. In multiple studies, MRSA nasal swabs has been shown to have a negative predictive value (NPV) of ~99% in non-oncology patients with pneumonia and other infections. At Yale New Haven Hospital (YNHH), a negative MRSA nasal swab is utilized in acute myeloid leukemia (AML) patients to de-escalate empiric MRSA antibiotic therapy. The primary endpoint was to assess the percentage of patients with a negative MRSA nasal swab who developed a culture documented (CD) MRSA infection during their admission. Secondary endpoints included the number of MRSA nasal swabs that were initially negative but converted to positive, and the types of MRSA infections. Methods This was a retrospective chart review of AML patients with a suspected infection and a MRSA nasal swab collected at YNHH between 2013 and 2018. Patients were excluded if < 18 years old, prior confirmed MRSA infection or positive MRSA nasal swab within the past year. Results 194 patients were identified with 484 discrete encounters analyzed. Hematopoietic stem cell transplantation occurred in 83 (43%) patients. A total of 468 (97%) encounters had a negative MRSA nasal swab upon admission with no CD MRSA infection during their hospitalization. Three encounters (0.6%) had a negative MRSA nasal swab with a subsequent CD MRSA infection during their admission. Identified infections were bacteremia (2) and pneumonia (1). Median duration from the negative MRSA nasal swab to CD infection was 16 days. Thirteen encounters (3%) had a positive MRSA nasal swab, 5 of which had a CD MRSA infection. Infections included bacteremia (3), pneumonia (2), and sputum with negative chest X-ray (1). MRSA nasal swab had a sensitivity of 57% (CI 0.56–0.58), specificity of 98% (CI 0.98–0.98) positive predictive value of 31% (CI 0.3–0.32), and NPV of 99% (CI 0.99–0.99). Conclusion The results of this retrospective study demonstrate that a negative MRSA nasal swab has a 99% NPV for subsequent MRSA infections in AML patients with no prior history of MRSA colonization or infection. Based on these findings, a negative MRSA nasal swab can help guide de-escalation of empiric MRSA antibiotic therapy in this immunosuppressed population. Disclosures All authors: No reported disclosures.

Predictive value of TP53 fluorescencein situhybridization in cytogenetic subgroups of acute myeloid leukemia

2011 ◽  
Vol 52 (4) ◽  
pp. 642-647 ◽  
Author(s):  
Sigal Tavor ◽  
Rachel Rothman ◽  
Tamar Golan ◽  
Nadia Voskoboinik ◽  
Ben-Zion Katz ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Predictive Value ◽  
Myeloid Leukemia ◽  
Acute Myeloid

Assessment of Bone Marrow Angiogenesis in Patients with Acute Myeloid Leukemia by Using Contrast-enhanced MR Imaging with Clinically Approved Iron Oxides: Initial Experience

Radiology ◽  
2007 ◽  
Vol 242 (1) ◽  
pp. 217-224 ◽  
Author(s):  
Lars Matuszewski ◽  
Thorsten Persigehl ◽  
Alexander Wall ◽  
Norbert Meier ◽  
Ralf Bieker ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Acute Myeloid Leukemia ◽  
Mr Imaging ◽  
Iron Oxides ◽  
Myeloid Leukemia ◽  
Initial Experience ◽  
Contrast Enhanced ◽  
Acute Myeloid

Residual Disease Monitoring in Childhood Acute Myeloid Leukemia by Multiparameter Flow Cytometry: The MRD-AML-BFM Study Group

2006 ◽  
Vol 24 (22) ◽  
pp. 3686-3692 ◽  
Author(s):  
Claudia Langebrake ◽  
Ursula Creutzig ◽  
Michael Dworzak ◽  
Ondrej Hrusak ◽  
Ester Mejstrikova ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Acute Myeloid Leukemia ◽  
Predictive Value ◽  
Myeloid Leukemia ◽  
Residual Disease ◽  
Multiparameter Flow Cytometry ◽  
Time Points ◽  
Significant Difference ◽  
Childhood Acute Myeloid Leukemia ◽  
Acute Myeloid

Purpose Monitoring of residual disease (RD) by flow cytometry in childhood acute myeloid leukemia (AML) may predict outcome. However, the optimal time points for investigation, the best antibody combinations, and most importantly, the clinical impact of RD analysis remain unclear. Patients and Methods Five hundred forty-two specimens of 150 children enrolled in the AML-Berlin-Frankfurt-Muenster (BFM) 98 study were analyzed by four-color immunophenotyping at up to four predefined time points during treatment. For each of the 12 leukemia-associated immunophenotypes and time points, a threshold level based on a previous retrospective analysis of another cohort of children with AML and on control bone marrows was determined. Results Regarding all four time points, there is a statistically significant difference in the 3-year event-free survival (EFS) in those children presenting with immunologically detectable blasts at 3 or more time points. The levels at bone marrow puncture (BMP) 1 and BMP2 turned out to have the most significant predictive value for 3-year-EFS: 71% ± 6% versus 48% ± 9%, PLog-Rank = .029 and 70% ± 6% versus 50% ± 7%, PLog-Rank = .033), resulting in a more than two-fold risk of relapse. In a multivariate analysis, using a combined risk classification based on morphologically determined blasts at BMP1 and BMP2, French-American-British classification, and cytogenetics, the influence of immunologically determined RD was no longer statistically significant. Conclusion RD monitoring before second induction has the same predictive value as examining levels at four different time points during intensive chemotherapy. Compared with commonly defined risk factors in the AML-BFM studies, flow cytometry does not provide additional information for outcome prediction, but may be helpful to evaluate the remission status at day 28.

Sign in / Sign up

Export Citation Format

Share Document